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OBJECTIVES: We performed a pharmacoeconomic 
evaluation of LHRH agonists (LAs) in treating metasta-
tic prostate cancer compared to standard care, as identi-
ﬁed in the literature and by clinical experts, including
estrogens (DES), orchiectomy, antiandrogens (AAs), and
combinations therapy (LAs + AAs).
METHODS: A Markov model was constructed to
perform a cost-effectiveness analysis (CEA) over 5 years,
from a Canadian provincial healthcare payer perspective.
Efﬁcacy of treatments was determined by meta-analysis
of clinical data.
RESULTS: In the base case analysis, DES was least costly
at $588, but also the least effective, with 1.11 expected
life-years (ELYs). The cost of orchiectomy was $830 with
a greater effectiveness of 1.71 ELYs, and an incremental
cost effectiveness ratio of $399/Life Year Gained (LYG)
over DES. AAs or LAs resulted in higher costs, $4,108
and $8,116 respectively, but lower effectiveness of 1.19
ELYs and 1.50 ELY respectively, thus were both 
dominated by orchiectomy. LAs + AAs was most costly
at $18,029, but with the highest effectiveness (1.89
ELYs), with an incremental cost effectiveness ratio 
of $97,301/LYG over orchiectomy. Changes in key-
parameters in sensitivity analyses did not affect the
ranking of the treatment strategies, suggesting that the
model was robust.
CONCLUSIONS: LAs were dominated by orchiectomy
in the base case analysis and most sensitivity analyses.
Combination therapy displayed incremental cost effec-
tiveness ratios over orchiectomy ranging from approxi-
mately $30,000 to $100,000 per LYG. Orchiectomy was
more effective, had fewer severe adverse reactions, and
cost slightly more than DES, the least expensive treat-
ment. However, due to potential psychological impact,
further research is warranted to examine its acceptance
by patients.
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Colorectal cancer (CRC) treatment is associated with
high costs, and hence, consideration of the cost-
effectiveness of available chemotherapeutic agents
becomes important in decision-making. Since use of a
single or few studies to guide allocative decisions may 
be misleading, critical reviews of all available data are
essential.
OBJECTIVE: To systematically review all published
pharmacoeconomic analyses of available chemotherapeu-
tic agents for the treatment of advanced CRC.
METHODS: Studies in English were identiﬁed from
Medline, CancerLit and HealthStar databases (1990–
2001) using key search terms: colorectal cancer,
chemotherapy, economics, and cost-effectiveness. Infor-
mation was abstracted from each study using an adapta-
tion of the cost-effectiveness analysis-reporting checklist
published by the Panel on Cost-Effectiveness in Health
and Medicine.
RESULTS: Of the 23 identiﬁed studies, only nine studies
were pharmacoeconomic analyses of chemotherapeutic
agents (5-ﬂuorouracil(FU)+levamisole/leucovorin,
irinotecan, raltitrexed). Of these nine, one failed to report
study perspective, two did not report the year of costs
while three failed to conduct sensitivity analyses. Most
studies used a payer perspective to model costs and sur-
vival was the most common end-point. Cost-effectiveness
estimates for adjuvant chemotherapy with 5-FU plus 
levamisole have been reported to be below $5,000/life-
year gained (LYG). The only study that adjusted for the
quality of survival resulted in a substantial decrease in
cost-effectiveness of chemotherapy using 5-FU and 
levamisole(Austr$2,916/LYG to $17,500/QALY). How-
ever, utilities were obtained from a small sample of
patients in this study. Estimates for irinotecan ranged
from cost savings to $10,137/LYG while raltitrexed has
been found to cost US$ 3,936 per additional patient
without severe adverse events when compared to 5-FU
regimens.
CONCLUSION: Pharmacoeconomic proﬁles of relatively
newer drugs such as irinotecan and raltitrexed look
promising but further research on their relative cost-
effectiveness is warranted to aid decision-makers. Future
cost-effectiveness research in advanced CRC patients
needs to incorporate the quality of the extended survival.
Stricter adherence to reporting guidelines for pharma-
coeconomic studies is also required.
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